Cancer Immunology, Immunotherapy

, Volume 38, Issue 3, pp 201–207 | Cite as

Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction

  • David W. Hoskin
  • Teresa Reynolds
  • Jonathan Blay
Original Articles Colon Cancer, Immune Suppression, Anti-CD3 Antibody, MHC-Unrestricted CTL
Received:
Accepted:
  • 37 Downloads

Abstract

Adoptive immunotherapy with lymphokine-activated killer (LAK) cells has shown some promise in the treatment of certain cancers that are unresponsive to conventional treatment approaches. However, colon adenocarcinomas tend to respond poorly to LAK therapy, possibly as a result of tumor-induced immunosupprression. Recently, in vivo administration of anti-CD3 antibody has been shown to induce mouse T lymphocytes to mediate major-histocompatibility-complex(MHC)-unrestricted tumoricidal activity which is distinet from natural-killer-cell-derived LAK activity. It has therfore been suggested that anti-CD3 therapy may find application in tumor immunotherapy in humans. However, the effectiveness of anti-CD3-activated killer cell induction within the environment found in the vicinity of colon adenocarcinoma cells has not been evaluated. The present report demonstrates that colon cancer cells of human (HT-29) and mouse (MCA-38) origin markedly inhibit the generation of activated killer cells in murine spleen cell cultures. DNA synthesis and interleukin-2 production by spleen cells following stimulation with anti-CD3 antibody are also profoundly depressed in the presence of MCA-38 and HT-29 adenocarcinoma cells. MCA-38- and HT-29-mediated inhibition of activated killer cell development is exerted through the production of a tumor-associated soluble factor that is distinct from transforming growth factor β or prostaglandins. Local immunosupression associated with sites of tumor growth may therefore represent a major obstacle to successful anti-CD3 immunotherapy of certain colon adenocarcinomas.

Key words

Colon cancer Immune supression Anti-CD3-antibody MHC-unrestricted CTL 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, Grieg R, (1989) Growth factor production by human colon carcinoma cell lines. Cancer Res 49: 2898PubMedGoogle Scholar
  2. 2.
    Belldegrun A, Kasid A, Uppenkamp M, Topalian S, Rosenberg SA (1989) Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA and relevance to cancer immunotherapy. J Immunol 142: 4520PubMedGoogle Scholar
  3. 3.
    Callewaert DM, Kaplan J, Peterson WD (1975) Suppression of lymphocyte activation by a factor produced byMycoplasma arginini. Immunol 115: 1662Google Scholar
  4. 4.
    Cummings K, Robertson R (1977) Prostaglandin: increased production by renal cell carcinoma. J Urol 118: 720PubMedGoogle Scholar
  5. 5.
    Dohi Y, Sunada S, Aoki M, Moriguchi A., Okabayashi M, Miyata M, Matsuda H (1993) Eadication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody. Cancer Immunol Immunother 36: 357PubMedGoogle Scholar
  6. 6.
    Dohlsten M, Sundstedt A, Bjorklund M, Hedlund G, Kalland T (1993) Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 54: 482PubMedGoogle Scholar
  7. 7.
    Ebert EC, Roberts AI, Devereux D, Nagase H (1990) Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res 50: 6158PubMedGoogle Scholar
  8. 8.
    Ellenhorn JDI, Hirsch R, Schreiber H, Bluestone A (1988) In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 242: 569PubMedGoogle Scholar
  9. 9.
    Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel L-H, Grau G, Bluestone J, Bach J-F, Chatenoud L (1990) Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 20: 509PubMedGoogle Scholar
  10. 10.
    Gallinger S, Hoskin DW, Mullen JBM, Wong AHC, Roder IC (1990) Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-I experimental hepatic metastasis in C57BL/6 mice. Cancer Res 50: 2476PubMedGoogle Scholar
  11. 11.
    Grimm EA, Muzumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomena. J Exp Med 155: 1823PubMedGoogle Scholar
  12. 12.
    Hoskin DW, Stankova J, Anderson SK, Roder JC (1989) Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibody. Cancer Immunol Immunother 29: 226PubMedGoogle Scholar
  13. 13.
    Huang SS, O'Grady P, Huang JS (1988) Hunman transforming growth factor β, α2-macroglobulin complex is a latent form of transforming growth factor β. J Biol Chem 263: 1535PubMedGoogle Scholar
  14. 14.
    Jin B, Scott JL, Vadas MA, Burns GF (1989) TGF-β down regulates TL: SA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 66: 570PubMedGoogle Scholar
  15. 15.
    June CH, Fletcher MC, Ledbetter JA, Schiever GL, Siegel JN, Phillips AF, Samelson LE (1990) Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci USA 87: 7722PubMedGoogle Scholar
  16. 16.
    Kupper MC, Hamou M, Bodmer S, Fontana A, de Tribolet N (1988) The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42: 562PubMedGoogle Scholar
  17. 17.
    Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl Acad Sci USA 84: 1374PubMedGoogle Scholar
  18. 18.
    Loeffler CM, Symth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, Tase JE, Urba WJ, Leonard AS, Young HA, Ochoa AC (1992) Immunoregulation in cancer-bearing hosts. Downregulation of gene expression and cytotoxic function in CD8+T cells. J Immunol 149: 949PubMedGoogle Scholar
  19. 19.
    Maraskovsky E, Chen W-F, Shortman K (1989) IL-2 and IFN-γ are two necessary lynphokines in the development of cytolytic T cells. J Immunol 143: 1210PubMedGoogle Scholar
  20. 20.
    Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7: 486PubMedGoogle Scholar
  21. 21.
    Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795PubMedGoogle Scholar
  22. 22.
    Mule JJ, Schwartz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor beta inhibits the in vitro generation of lymphokine-activated killeer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95PubMedGoogle Scholar
  23. 23.
    Nelson DS, Nelson M (1987) Evasion of host defenses by tumors. Immunol Cell Biol 65: 287PubMedGoogle Scholar
  24. 24.
    Phillips JH, Lanier LL (1986) Disection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814PubMedGoogle Scholar
  25. 25.
    Pillay DJ, Karmazyn M, Pope BL (1986) Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: modulatory role of prostaglandins. Int J Immunopharmacol 8: 227PubMedGoogle Scholar
  26. 26.
    Rice SQJ, Crane IJ, Scully C, Prime SS (1992) Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cells lines. Scand J Immunol 36: 443PubMedGoogle Scholar
  27. 27.
    Roberts AB, Sporn MB (1988) Transforming growth factor beta. Adv Cancer Res 51: 107PubMedGoogle Scholar
  28. 28.
    Salmon SE, Sartorelli AC (1992) Cancer chemotherapy. In: BG Katzung (ed) Basic and clinical pharmacology (5th edn.). Appleton and Lange: Norwalk, pp. 766–800Google Scholar
  29. 29.
    Stankova J, Hoskin DW, Roder JC (1989), Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations. Cell Immunol 121: 13PubMedGoogle Scholar
  30. 30.
    Tsang M, Weatherbee JA, Dietz M, Kitamura T, Lucas RC (1990) TGF-beta specifically inhibits the IL-4-dependent proliferation of multifactor-dependent murine T helper and human hematopoietic cell lines. Lymphokine Res 9: 607Google Scholar
  31. 31.
    Watson GA, Fu Y-X, Lopez DM (1991) Splenic macrophages from tumor-hearing mice co-experissing. Mac-1 and Mac-2 antigens exert immunoregulatory funtions via two distinet mechanisms. J Leukoc Biol 49: 126PubMedGoogle Scholar
  32. 32.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • David W. Hoskin
    • 2
  • Teresa Reynolds
    • 2
  • Jonathan Blay
    • 1
  1. 1.Department of PharmacologyDalhousie UniversityHalifaxCanada
  2. 2.Department of Microbiology and ImmunologyDalhousie UniversityHalifaxCanada

Personalised recommendations